2017 American Transplant Congress
Pre-Transplant CMV-Specific T-Cell Immunity Is an Additional Independent Variable Predicting CMV Infection After Kidney Transplantation.
Background: Current pre-transplant risk stratification for Cytomegalovirus (CMV) infection is based on donor/recipient (D/R) IgG-serostatus and clinical variables such as the use of T-cell depletion…2017 American Transplant Congress
CMV-Infected Kidney Grafts Drive the Expansion of Blood-Born CMV-Specific T-Cells Restricted by Shared HLA Molecules Through Presentation on Donor's Cells.
Background. Cytomegalovirus specific immune response is crucial to control CMV infection in kidney transplant recipients (KTR), in whom recipient CMV can reactivated (R+) and donor…2017 American Transplant Congress
More Rapid Decline in Male VS Female Living Kidney Donations (LKD) Varies by Income.
Reasons for the decline in LKD remain uncertain. We hypothesized that there would be a more rapid decline in male vs female LKD and that…2017 American Transplant Congress
Personalizing Immunosuppression with Molecular Phenotyping in Pediatric Liver Transplantation.
Pediatric Abdominal Transplant, Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Background: Optimizing immunosuppression requires selecting an agent which can inhibit the dominant anti-rejection mechanism in individual children with liver transplantation (LTx). Extended use of steroids,…2017 American Transplant Congress
Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients.
Drugs are classified as highly variable when intra-patient coefficient of variation (CV%) is > 30%. Tacrolimus (TAC) is characterized as highly variable often without supporting…2017 American Transplant Congress
Extended Experience with Tocilizumab (Anti-IL6R) for Difficult to Desensitize (Des) Patients Awaiting HLA Incompatible Kidney Transplant.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: ~30% of HS patients fail to respond to DES with IVIG+rituximab. IL6/IL-6R signaling is critical for B-cell differentiation to plasmablasts and IgG production. Tocilizumab…
American Transplant Congress abstracts